Sleep Apnea

The FDA has authorized the marketing of eXciteOSA, a prescription device for the reduction of snoring and mild obstructive sleep apnea, according to a press release.

Effects of cardiac resynchronization therapy vs. right ventricular pacing for central sleep apnea in patients with pacing-induced cardiomyopathy.

Sleep could have a significant effect on CV health and long-term CV outcomes, and factors such as obstructive sleep apnea and sleep duration may warrant consideration among patients with hypertension, a speaker reported.

Five-year data show sustained safety and efficacy outcomes after implantation of a transvenous phrenic nerve stimulation device in adults with moderate to severe central sleep apnea.

Obstructive sleep apnea increases the risk for central serous chorioretinopathy in both men and women, according to a study published in American Journal of Ophthalmology.

Central sleep apnea was common in patients with pacing-induced cardiomyopathy and may improve with cardiac resynchronization therapy compared with right ventricular pacing, researchers found in the UPGRADE trial.

Patients with obstructive sleep apnea could have an increased risk for adverse COVID-19 outcomes, according to a systematic review published in Sleep Medicine Reviews.

Primary care physicians’ and sleep specialists’ adherence to recommendations for diagnosing obstructive sleep apnea was “fair with low failure rates,” according to researchers.

The severity of obstructive sleep apnea may be associated with the thinning of the superotemporal retinal nerve fiber layer, according to findings published in the Journal of Glaucoma.

In this video, Shalini Paruthi, MD, co-chair of the SLEEP 2020 meeting — hosted by the Associated Professional Sleep Societies — discusses sessions at the virtual meeting that provide insight into testing, diagnosis and treatment of sleep disorders.